Background Many asthmatic patients exhibit sputum eosinophilia associated with
exacerbations. Benralizumab targets eosinophils by binding IL-5 receptor α, inducing
apoptosis through antibody-dependent cell-mediated cytotoxicity. Objectives We sought to
evaluate the safety of benralizumab in adults with eosinophilic asthma and its effects on
eosinophil counts in airway mucosal/submucosal biopsy specimens, sputum, bone marrow,
and peripheral blood. Methods In this multicenter, double-blind, placebo-controlled phase I …